BRIEF-Alnylam Completes NDA Submission To U.S. FDA For Patisiran For Treatment Of HATTR Amyloidosis
December 12, 2017 at 07:37 AM EST
* ALNYLAM COMPLETES SUBMISSION OF NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR PATISIRAN FOR THE TREATMENT OF HEREDITARY ATTR (HATTR) AMYLOIDOSIS Source text for Eikon: Further company coverage:
